keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,734
- Likes Received
- 4,524
Here are some scholarly articles on mazdutide. I included hyperlinks to the full articles for most but not all of the citations. I used bold type for the article that I believe to be most revealing.
Anderson (2025). Emerging concepts in obesity managemen -: focus on glucagon receptor agonist combinations. Drugs Context, 14.
Deng, et al. (2024). Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity - A systematic review and meta-analysis of randomized controlled trials. Endocrine, 86(1), 15-27. https://doi.org/10.1007/s12020-024-03857-6
Ji, et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications, 14(1), 8289.
Ji, et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med, 392(22), 2215-2225.
Ji, et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity - a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine, 54.
Liu (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with-without type 2 diabetes - a systematic review and network meta-analysis. Frontiers in Endocrinology, 16, 1513641.
Moiz, et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes - a systematic review of randomized controlled trials. Annals of Internal Medicine, 178(2), 199-217. https://doi.org/10.7326/ANNALS-24-01590; https://www.acpjournals.org/doi/abs/10.7326/ANNALS-24-01590.
Nalisa, et al. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients - a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 15, 1309118.
Newswire, P. R. Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.
Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 161, 156038.
Zhang, et al. (2024). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes 0 a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168.
Anderson (2025). Emerging concepts in obesity managemen -: focus on glucagon receptor agonist combinations. Drugs Context, 14.
Deng, et al. (2024). Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity - A systematic review and meta-analysis of randomized controlled trials. Endocrine, 86(1), 15-27. https://doi.org/10.1007/s12020-024-03857-6
Ji, et al. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications, 14(1), 8289.
Ji, et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med, 392(22), 2215-2225.
Ji, et al. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity - a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine, 54.
Liu (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with-without type 2 diabetes - a systematic review and network meta-analysis. Frontiers in Endocrinology, 16, 1513641.
Moiz, et al. (2025). Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes - a systematic review of randomized controlled trials. Annals of Internal Medicine, 178(2), 199-217. https://doi.org/10.7326/ANNALS-24-01590; https://www.acpjournals.org/doi/abs/10.7326/ANNALS-24-01590.
Nalisa, et al. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients - a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 15, 1309118.
Newswire, P. R. Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions.
Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 161, 156038.
Zhang, et al. (2024). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes 0 a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168.
